446 related articles for article (PubMed ID: 31930374)
1. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Mullin S; Smith L; Lee K; D'Souza G; Woodgate P; Elflein J; Hällqvist J; Toffoli M; Streeter A; Hosking J; Heywood WE; Khengar R; Campbell P; Hehir J; Cable S; Mills K; Zetterberg H; Limousin P; Libri V; Foltynie T; Schapira AHV
JAMA Neurol; 2020 Apr; 77(4):427-434. PubMed ID: 31930374
[TBL] [Abstract][Full Text] [Related]
2. Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation.
Siemeling O; Slingerland S; van der Zee S; van Laar T
BMC Neurol; 2024 May; 24(1):146. PubMed ID: 38693511
[TBL] [Abstract][Full Text] [Related]
3. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Silveira CRA; MacKinley J; Coleman K; Li Z; Finger E; Bartha R; Morrow SA; Wells J; Borrie M; Tirona RG; Rupar CA; Zou G; Hegele RA; Mahuran D; MacDonald P; Jenkins ME; Jog M; Pasternak SH
BMC Neurol; 2019 Feb; 19(1):20. PubMed ID: 30738426
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
den Heijer JM; Kruithof AC; Moerland M; Walker M; Dudgeon L; Justman C; Solomini I; Splitalny L; Leymarie N; Khatri K; Cullen VC; Hilt DC; Groeneveld GJ; Lansbury P
Mov Disord; 2023 Jul; 38(7):1197-1208. PubMed ID: 37195859
[TBL] [Abstract][Full Text] [Related]
6. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Yang SY; Taanman JW; Gegg M; Schapira AHV
Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
[TBL] [Abstract][Full Text] [Related]
7. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.
Menozzi E; Toffoli M; Schapira AHV
Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432
[TBL] [Abstract][Full Text] [Related]
8. A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.
Yang SY; Beavan M; Chau KY; Taanman JW; Schapira AHV
Stem Cell Reports; 2017 Mar; 8(3):728-742. PubMed ID: 28216145
[TBL] [Abstract][Full Text] [Related]
9. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
10. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
Yang SY; Gegg M; Chau D; Schapira A
Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
[TBL] [Abstract][Full Text] [Related]
12. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.
Migdalska-Richards A; Ko WKD; Li Q; Bezard E; Schapira AHV
Synapse; 2017 Jul; 71(7):. PubMed ID: 28295625
[TBL] [Abstract][Full Text] [Related]
13. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
14. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
15. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.
Menozzi E; Schapira AHV
CNS Drugs; 2020 Sep; 34(9):915-923. PubMed ID: 32607746
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.
Lerche S; Wurster I; Roeben B; Zimmermann M; Riebenbauer B; Deuschle C; Hauser AK; Schulte C; Berg D; Maetzler W; Waniek K; Lachmann I; Liepelt-Scarfone I; Gasser T; Brockmann K
Mov Disord; 2020 Mar; 35(3):495-499. PubMed ID: 31670439
[TBL] [Abstract][Full Text] [Related]
18. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
19. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D
Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808
[TBL] [Abstract][Full Text] [Related]
20. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.
Migdalska-Richards A; Daly L; Bezard E; Schapira AH
Ann Neurol; 2016 Nov; 80(5):766-775. PubMed ID: 27859541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]